Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Total Current Liabilities (2016 - 2025)

Apyx Medical's Total Current Liabilities history spans 16 years, with the latest figure at $11.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 9.13% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $11.7 million, up 9.13%, while the annual FY2025 figure was $11.7 million, 9.13% up from the prior year.
  • Total Current Liabilities reached $11.7 million in Q4 2025 per APYX's latest filing, up from $11.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $19.0 million in Q2 2023 to a low of $9.5 million in Q1 2025.
  • Average Total Current Liabilities over 5 years is $11.8 million, with a median of $11.1 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: surged 67.63% in 2023, then tumbled 44.09% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $13.2 million in 2021, then fell by 10.26% to $11.8 million in 2022, then rose by 7.51% to $12.7 million in 2023, then dropped by 15.85% to $10.7 million in 2024, then rose by 9.13% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Total Current Liabilities are $11.7 million (Q4 2025), $11.0 million (Q3 2025), and $10.6 million (Q2 2025).